



PRESS RELEASE

FOR IMMEDIATE RELEASE

Invictus appoints Richard Estalella as Advisor for US Nutraceuticals

Melbourne Victoria (9 May 2018) – Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Mr Richard Estalella as an Advisor for the Company's launch of its nutraceutical products in the US.

Mr Estalella was previously the President of MusclePharm Corp in the US, a company with sports nutrition products sold globally. During Mr Estalella's tenure as Chief Operating Officer and later President, the Company expanded into 50,000 retail outlets and 120 countries along with sales revenue growth from US\$67M in 2012 to US\$167M in 2015.

Mr Estalella will manage the manufacture, distribution and sales of Invictus Biotechnology's two nutraceutical products, nE1-Heart™ (which maintains heart health) and nE1-Elite™ (which reduces after exercise soreness, improves muscle recovery and improves peak muscle power maintenance) in the US.

Invictus Biotechnology will be incorporating a US subsidiary in H2 of 2018 and the intention is for Mr. Estalella to be appointed the President and CEO of this US-based company.

Invictus Biotechnology's Executive Chairman, Dr Glenn Tong, said:

"Richard is a seasoned executive who has been operating very successfully in the US sports nutrition market and we are delighted that he has agreed to play an integral role in the launch of our nutraceuticals in the US".



“The branding for Invictus’ two nutraceutical products is both novel and credible, and in particular, nE1-Elite™ is unique, addresses a significant unmet need and a market which is not only large but also growing rapidly. I am very excited about joining the Invictus team and taking the lead on the launch of these two exciting products in the US” added Mr Estalella.

Investor and Media Enquiries:

Dr Douglas Pretsell, Investor and Media Relations
Ph: +61 (0) 409 908 553

Corporate enquiries:

Dr Glenn Tong, Executive Chairman
Ph: +61 (0) 412 193 350

About Invictus Biotechnology

Invictus Biotechnology Pty. Ltd. is a private Australian biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, hyperlipidaemia, hypertension and diabetes. Invictus Biotechnology owns and controls patent and other intellectual property rights for novel approaches to delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

About Richard Estalella

Richard Estalella is an experienced executive and Board director who has a successful track record in the Retail, Multi-Level Marketing and the Sports Nutrition industry. Richard was the Chief Operating Officer and then President of MusclePharm Corp in the US (OTCQB:MSLP) which during his tenure increased distribution to 50,000 retail outlets and 120 countries along with sales revenue growth from US\$67M in 2012 to US\$167M in 2015. He oversaw operations, finance and supply chain which included the development of global manufacturing capabilities.